The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

NCT07482943 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Fontan
Heart Failure
Dapagliflozin
Cardiovascular Diseases
Sodium-GLucose coTransporter-2 Inhibitors

Interventions

DRUG: Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy

Sponsor

The University of Hong Kong